Bioceres Crop Solutions Reports Fiscal Second Quarter 2022 Financial and Operational Results

Rhea-AI Summary

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) reported a strong fiscal second quarter 2022, with comparable revenues increasing 89% YoY to $90.3 million and LTM Adjusted EBITDA hitting $61.8 million, up 46%. Revenue growth was driven by inoculants, seed treatments, and micro-beaded fertilizers. The company anticipates peak revenue from HB4 Wheat at $195 million and an EBITDA target of $15-20 million for FY2024. The successful regulatory approval for HB4 wheat flour in Brazil marks a crucial step for commercial launch, with inventories stabilizing towards market demand.

Positive

• Comparable revenues increased 89% YoY to $90.3 million.
• LTM Adjusted EBITDA rose 46% YoY to $61.8 million.
• Growth driven by inoculants, seed treatments, and fertilizers, with 146% growth in Europe and the U.S.
• Peak revenue opportunity for HB4 Wheat estimated at $195 million.
• Incremental EBITDA target for HB4 Wheat set at $15-20 million for FY2024.

Negative

• HB4 pre-launch costs totaled $6.2 million, impacting reported EBITDA.
• Rollout of new HB4 Soy varieties affected by late season drought.

2Q22 Comparable Revenues up 89% YoY – Baseline Business Adjusted EBITDA up 48% in the first two quarters, reaching $61.8M LTM

HB4 Wheat maintains performance as grower exposure increases more than 8X. Brazil regulatory approval and inventory levels in place for 4Q22 limited launch

HB4 Wheat opportunity estimated at $195M at peak revenues in current market, with incremental EBITDA target of $15-20M set for FY2024

ROSARIO, Argentina--(BUSINESS WIRE)-- Bioceres Crop Solutions Corp. (“Bioceres”) (NASDAQ: BIOX), a fully integrated provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, has reported financial results for the second quarter 2022, ended December 31, 2021. Financial results are expressed in US dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (“YoY”), unless otherwise noted.

FISCAL SECOND QUARTER FINANCIAL HIGHLIGHTS

• Comparable Revenues increased 89% in 2Q22, to $90.3 million, up from $47.7 million in the year-ago quarter, resulting in an accumulated growth of 72% year to date. Growth in revenues was mainly driven by inoculants across various geographies globally, seed treatment packs in South America, and a successful high-season marketing of micro-beaded fertilizers in Argentina. The combined growth in Europe and the United States reached 146% YoY during the quarter.
• Comparable Gross Profit for the quarter was up 69%, compared to the year-ago quarter, reaching $42.2 million. Year-to-date comparable gross profit reached $70.1 million, up 56% compared to fiscal year 2021. With all regions' nominally growing contributions to gross profit compared to the year-ago quarter, Europe and the United States stood out, representing approximately 15% of total gross profit, up from 11% in 2Q21.
• LTM Adjusted EBITDA for the Baseline Business, which excludes HB4 pre-launch costs, reached $61.8 million, up 46% compared to the year-ago metric, and 15% on a quarterly sequential basis. LTM HB4 pre-launch expenses comprised of SG&A, inventory ramp-up and data acquisition costs, totaled $6.2 million - inclusive of a $1.9 million negative IAS29 accounting adjustment to HB4 grain inventories - leading to a reported LTM Adjusted EBITDA of $55.6 million. HB4 pre-launch costs are expensed as incurred and accounted for in SG&A and Other Income or Loss, both line items with an impact in reported Adjusted EBITDA. Upon completion of the harvest season, HB4 Wheat seed inventory has reached the required level for a limited commercial launch, stabilizing the run rate of inventory ramp-up costs.
• Bioceres’ subsidiary Rizobacter Argentina S.A. completed a $20.0 million public offering of series VII corporate bonds, which mature in December 2024 and pay an annual nominal interest rate of 1.49%. Proceeds allowed Bioceres to maintain a strong liquidity position of $39.9 million by quarter-end and increased the long-term portion of total debt from 63% to 74%, stabilizing the average cost of debt at 7.1%. Net Financial Debt to LTM Adjusted EBITDA ratio decreased from 2.74x to 2.66x on a sequential basis.

FISCAL SECOND QUARTER HB4 HIGHLIGHTS

• HB4 Wheat outyielded non-HB4 varieties, with a 12.8% average increase across all environments and locations. In targeted environments, representing more than one-third of all harvested hectares, the average yield improvement was 49%. 2^nd generation varieties showed a 16% yield improvement in high yielding environments, when compared to 1^st generation materials.
• Brazil's regulatory authority, CTNBio, granted the import approval for HB4 wheat flour for animal and human consumption in November 2021. This approval is a major milestone in Bioceres’ mission to build agricultural systems that enhance carbon sequestration and climate resiliency, and a necessary step for a commercial launch in the upcoming planting season.
• Estimations based on growers’ feedback, portfolio of varieties and seed multiplication plans set EBITDA target for HB4 Wheat at $15-20 million for FY2024. Opportunity peak estimated at 2.3 million hectares and $195 million in revenues for the Company in current market.
• Rollout of new HB4 Soy varieties affected by reduction in late season plantings due to severe drought conditions during December. Top-performing 3^rd generation HB4 varieties planted at 100% of available inventory, while 2^nd generation materials planted on 60% of planned hectares. 1^st generation varieties fully discontinued as indicated in 4Q21. Shift towards new varieties expected to unlock further yield gains going forward.
• Alexandre Garcia joined the management team as Global Head of Seed Business to enhance focus on accessing and developing top performing genetics for the HB4 trait and new technologies. In his former position as Innovation and Research Director at TMG, a leading provider of soybean genetics for Latin America, Alexandre led the collaboration efforts on HB4 in Brazil since 2014. ​He completed a PhD in Agronomy at the State University of Maringa (Brazil) / University of Illinois (US), an MBA from Fundação Getulio Vargas (Brazil), and has more than 15 years of experience in the seed business.

MANAGEMENT REVIEW

Mr. Federico Trucco, Chief Executive Officer of Bioceres, commented: “We are thrilled to report a record setting quarter for our Company, with comparable revenues at $90.3 million and LTM Adjusted EBITDA at $61.8 million, excluding HB4 pre-launch costs. Our very strong performance during the second quarter contributed to a 72% growth in revenues year-to-date, with robust growth across all three business segments. We are also very proud to report that our combined growth in Europe and the United States (at 146% for the period) places these important geographies close to 10% of our global revenues, a huge step forward in our international diversification strategy”.

“On the HB4 front, I would like to mention the announcement in November by the Brazilian National Biosafety Commission (CTNBio), that decided unanimously to approve the import certification for HB4 wheat flour for human and animal consumption in that country. This approval is a major milestone and a key step in Bioceres’ mission to build agricultural systems that enhance carbon sequestration and climate resiliency, and is a necessary step for a commercial launch in the upcoming planting season. We are now in a position to estimate an incremental EBITDA contribution for HB4 Wheat of $15-20M for fiscal year 24”, concluded Trucco.

Mr. Enrique Lopez Lecube, Chief Financial Officer of Bioceres, added, “We had a great quarter that built on top of the momentum our business had experienced in previous quarters; LTM adjusted EBITDA excluding HB4 pre-launch costs grew 46% year over year and 15% on a sequential basis. The main drivers behind the quarter’s numbers were a remarkable commercial performance and market penetration of scaling technologies. Micro-beaded fertilizers delivered record growth, while inoculants and seed treatment pack sales were outstanding in North America and Europe. It is exciting to think about the prospect of adding to this business the EBITDA target we have now set for HB4 Wheat.”

“During the quarter we further fortified our balance sheet with a $20 million issuance of 3-year maturity corporate bonds in our subsidiary Rizobacter. The strong financial performance of our baseline business combined with a stable debt structure and liquidity position provides a solid foundation for growth,” concluded Lecube.

Key Operational Metrics (In millions of US dollars, unless where otherwise stated)

Table 1: Key Financial Metrics
2Q22	As Reported		% Change
Revenue by Segment	2Q21	2Q22	Reported	Comparable1
Crop Protection	27.1	47.3	75%	76%
Seed and Integrated Products	12.5	16.1	29%	26%
Crop Nutrition	9.2	29.3	218%	212%
Total Revenue	48.7	92.7	90%	89%
Gross Profit	23.7	37.3	58%	69%
Gross Margin	48.6%	40.3%	(827 bps)	(563 bps)
Adjusted EBITDA	14.3	19.7	38%
HB4 pre-launch costs	0.2	3.0	1461%
Baseline Business Adjusted EBITDA	14.5	22.7	57%
Baseline Business Adjusted EBITDA Margin	29.7%	24.5%	(524 bps)
1. Comparable excludes the impact of IAS29 as discussed in more detail on page 15.

Table 2: HB4 Wheat Metrics
Hectares	Number of Varieties	Growers	Contributed goods1
FY20 7,000	FY20 2 (1st Gen)	FY20 25	FY20 1.4M
FY21 53,000	FY21 3 (1st Gen)	FY21 225	FY21 6.4M
∆ 657%	4 (2nd Gen)	∆ 800%	∆ 303%

Table 3: HB4 Soy Metrics
Hectares	Number of Varieties	Growers	Contributed goods1
FY21 23,000	FY21 4 (1st Gen)	FY21 148	FY21 2.2M
FY22 23,000	3 (2nd Gen)	FY22 102	FY22 2.0M
∆ -%	FY22 3 (2nd Gen)	∆ (31%)	∆ (10%)
	9 (3rd Gen)

¹ Metric will be used to account for and track the underlying economic performance of our HB4 Wheat and HB4 Soy Program ahead of reporting HB4 revenues and related accounting measures. By publishing the level of contributed goods, the investment community can also use this information to better gauge our progress.

For a full version of Bioceres Fiscal Second Quarter 2022 Earnings Release, click here.

FISCAL SECOND QUARTER 2022 EARNINGS CONFERENCE CALL

Bioceres Chairman & Chief Executive Officer Federico Trucco, Chief Financial Officer Enrique Lopez Lecube and Head of Investor Relations Rodrigo Krause will host the conference call followed by a question-and-answer session. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of the company’s website here.

To access the call, please use the following information:

Date:	Thursday, February 10, 2022
Time:	8:30 a.m. EST, 5:30 a.m. PST
Toll Free dial-in number:	1-844-200-6205
Toll/International dial-in number:	1-929-526-1599
Conference ID:	510191
Webcast:	Click here

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have difficulty connecting with the conference call, please contact MZ Group at +1 (949) 491-8235.

The conference call will be broadcast live and available for replay here and via the investor relations section of the company’s website here.

A replay of the call will be available through February 17, 2022 following the conference.

Toll Free Replay Number:	1-866-813-9403
International Replay Number:	+44 204 525 0658
Replay ID:	510901

About Bioceres Crop Solutions Corp.

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) is a fully integrated provider of crop productivity technologies designed to enable the transition of agriculture towards carbon neutrality. To do this, Bioceres’ solutions create economic incentives for farmers and other stakeholders to adopt environmentally friendlier production practices. The Company has a unique biotech platform with high-impact, patented technologies for seeds and microbial ag-inputs, as well as next generation Crop Nutrition and Protection solutions. Through its HB4® program, the Company is bringing digital solutions to support growers’ decisions and provide end-to-end traceability for production outputs. For more information, visit here.

Forward-Looking Statements

This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include estimated financial information and, among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses by governments, clients and the Company, on our business, financial condition, liquidity position and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. These forward-looking statements include, but are not limited to, whether (i) the health and safety measures implemented to safeguard employees and assure business continuity will be successful, (ii) the uncertainty related to COVID-19 in the farming community will be short lived, and (iii) we will be able to coordinate efforts to ramp up inventories. Such forward-looking statements are based on management’s reasonable current assumptions, expectations, plans and forecasts regarding the Company’s current or future results and future business and economic conditions more generally. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, levels of activity, performance or achievement of the Company to be materially different from any future results expressed or implied by such forward-looking statements, and there can be no assurance that actual results will not differ materially from management’s expectations or could affect the Company’s ability to achieve its strategic goals, including the uncertainties relating to the impact of COVID-19 on the Company’s business, operations, liquidity and financial results and the other factors that are described in the sections entitled “Risk Factors” in the Company's Securities and Exchange Commission filings updated from time to time. The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. Therefore, you should not rely on any of these forward-looking statements as predictions of future events. All forward-looking statements contained in this release are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are or were made, and the Company does not intend to update or otherwise revise the forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, except as required by law.

Unaudited Consolidated Statement of Comprehensive Income (Figures in US dollars)
	Three-month period ended 12/31/2021	Three-month period ended 12/31/2020		Six-month period ended 12/31/2021	Six-month period ended 12/31/2020
Total revenue	92,662,853	48,738,690		159,679,098	91,093,951
Cost of sales	(55,332,989)	(25,073,842)		(93,325,442)	(48,186,484)
Gross profit	37,329,864	23,664,848		66,353,656	42,907,467
% Gross profit	40%	49%		42%	47%
Operating expenses	(20,198,593)	(12,334,536)		(37,813,335)	(23,450,991)
Share of profit of JV	1,141,323	65,975		919,087	305,687
Other income or expenses, net	(571,365)	135,132		(1,717,982)	140,322
Operating profit	17,701,229	11,531,419		27,741,426	19,902,485
Finance result	(8,221,621)	(5,896,874)		(13,401,289)	(18,632,336)
Profit before income tax	9,479,608	5,634,545		14,340,137	1,270,149
Income tax	(4,141,102)	(3,835,587)		(6,736,415)	(5,841,453)
Profit/ (Loss) for the period	5,338,506	1,798,958		7,603,722	(4,571,304)
Other comprehensive profit / (loss)	5,472,717	658,996		11,201,854	795,127
Total comprehensive Profit / (Loss)	10,811,223	2,457,954		18,805,576	(3,776,177)
Profit / (loss) for the period attributable to:
Equity holders of the parent	3,427,093	648,193		4,301,230	(6,323,365)
Non-controlling interests	1,911,413	1,150,765		3,302,492	1,752,061
	5,338,506	1,798,958		7,603,722	(4,571,304)
Total comprehensive income / (loss) attributable to:
Equity holders of the parent	7,660,743	1,244,596		13,382,802	(5,789,271)
Non-controlling interests	3,150,480	1,213,358		5,422,774	2,013,094
	10,811,223	2,457,954		18,805,576	(3,776,177)

Unaudited Consolidated Statement of Financial Position (Figures in US dollars)
ASSETS	12/31/2021	06/30/2021
CURRENT ASSETS
Cash and cash equivalents	36,187,804	36,046,113
Other financial assets	3,696,803	11,161,398
Trade receivables	119,285,056	88,784,172
Other receivables	17,822,854	11,153,705
Income and minimum presumed income taxes recoverable	1,072,748	990,881
Inventories	87,308,712	61,037,551
Biological assets	8,142,920	2,315,838
Total current assets	273,516,897	211,489,658
NON-CURRENT ASSETS
Other financial assets	832,159	1,097,462
Trade receivables	121,234	135,739
Other receivables	1,810,645	2,543,142
Income and minimum presumed income taxes recoverable	31,112	12,589
Deferred tax assets	5,689,401	3,278,370
Investments in joint ventures and associates	34,054,957	30,657,173
Property, plant and equipment	48,946,555	47,954,596
Intangible assets	72,563,018	67,342,362
Goodwill	29,904,359	28,751,206
Right-of-use leased asset	1,488,608	1,327,660
Total non-current assets	195,442,048	183,100,299
Total assets	468,958,945	394,589,957
LIABILITIES	12/31/2021	06/30/2021
CURRENT LIABILITIES
Trade and other payables	107,583,347	72,091,408
Borrowings	48,141,499	76,785,857
Employee benefits and social security	6,472,078	4,680,078
Deferred revenue and advances from customers	7,110,046	6,277,313
Income tax payable	11,687,238	7,452,891
Lease liabilities	635,240	750,308
Total current liabilities	181,629,448	168,037,855
NON-CURRENT LIABILITIES
Borrowings	90,738,228	47,988,468
Government grants	-	784
Investments in joint ventures and associates	616,173	1,278,250
Deferred tax liabilities	24,597,731	25,699,495
Provisions	484,490	449,847
Consideration for acquisitions	12,443,071	11,790,533
Convertible notes	48,890,332	48,664,012
Lease liability	570,505	390,409
Total non-current liabilities	178,340,530	136,261,798
Total liabilities	359,969,978	304,299,653
EQUITY
Equity attributable to owners of the parent	81,743,560	67,743,242
Non-controlling interests	27,245,407	22,547,062
Total equity	108,988,967	90,290,304
Total equity and liabilities	468,958,945	394,589,957

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20220210005420/en/

Investor Relations Contact

Chris Tyson

Executive Vice President

MZ Group – MZ North America

(949) 491-8235

BIOX@mzgroup.us

www.mzgroup.us

Bioceres Crop Solutions

Rodrigo Krause

Head of Investor Relations

investorrelations@biocerescrops.com

Source: Bioceres Crop Solutions Corp.

FAQ

What were Bioceres' revenues for 2Q22?

Bioceres reported comparable revenues of $90.3 million for the second quarter of 2022, an increase of 89% YoY.

What is the EBITDA target for HB4 Wheat in FY2024?

Bioceres has set an EBITDA target for HB4 Wheat at $15-20 million for fiscal year 2024.

What is the impact of HB4 Wheat's regulatory approval in Brazil?

The regulatory approval for HB4 wheat flour in Brazil is a key milestone for Bioceres, crucial for its upcoming commercial launch.

How did the company's financial position change in 2Q22?

Bioceres maintained a strong liquidity position of $39.9 million and decreased its net financial debt to LTM Adjusted EBITDA ratio to 2.66x.